Cansino Biotech (06185): DTCP-HIB-MCv4 combination vaccine initiated phase I clinical trial and completed the first patient enrollment

Zhitong Finance App News, Cansino Biotech (06185) announced that the adsorbed acell-free 100 (component) haemophilus influenzae type b (conjugate) (Hib) -ACYW135 meningococcus (conjugate) (MCV4) vaccine (DTCP-HIB-MCv4 combination vaccine) developed by the company recently officially launched a phase I clinical trial and completed the enrollment of the first test subjects.

Based on the company's product pipeline layout, combined with market demand for multiple vaccines, and forming differentiated competition, the company plans to develop the DTCP-HIB-MCv4 combination vaccine. The phase I clinical trial was to evaluate the safety and immunogenicity of the DTCP-HIB-MCv4 combination vaccine in people aged 2 months to 6 years.